MA32621B1 - Traitement de maladie auto-immune et inflammatoire - Google Patents
Traitement de maladie auto-immune et inflammatoireInfo
- Publication number
- MA32621B1 MA32621B1 MA33682A MA33682A MA32621B1 MA 32621 B1 MA32621 B1 MA 32621B1 MA 33682 A MA33682 A MA 33682A MA 33682 A MA33682 A MA 33682A MA 32621 B1 MA32621 B1 MA 32621B1
- Authority
- MA
- Morocco
- Prior art keywords
- autoimmune
- treatment
- inflammatory disease
- biological activity
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouveaux procédés de traitement de la sclérose en plaques et d'autres maladies auto-immunes ou troubles inflammatoires, et des antagonistes, comprenant des protéines de liaison isolées pour une utilisation dans les nouveaux procédés. La présente invention concerne en outre un procédé de traitement de la sclérose en plaques comprenant la neutralisation de l'activité biologique de il-7 par liaison à cd127 ou il-7. Les protéines de liaison isolées peuvent également neutraliser l'activité biologique de tslp.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8729408P | 2008-08-08 | 2008-08-08 | |
US16980109P | 2009-04-16 | 2009-04-16 | |
US21862709P | 2009-06-19 | 2009-06-19 | |
PCT/US2009/053136 WO2010017468A1 (fr) | 2008-08-08 | 2009-08-07 | Traitement de maladie auto-immune et inflammatoire |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32621B1 true MA32621B1 (fr) | 2011-09-01 |
Family
ID=41382165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33682A MA32621B1 (fr) | 2008-08-08 | 2011-03-08 | Traitement de maladie auto-immune et inflammatoire |
Country Status (23)
Country | Link |
---|---|
US (2) | US20110287000A1 (fr) |
EP (1) | EP2318442A1 (fr) |
JP (1) | JP2011530533A (fr) |
KR (1) | KR20110044777A (fr) |
CN (1) | CN102177179A (fr) |
AR (1) | AR072985A1 (fr) |
AU (1) | AU2009279471A1 (fr) |
BR (1) | BRPI0916945A2 (fr) |
CA (1) | CA2733432A1 (fr) |
CL (1) | CL2011000269A1 (fr) |
CO (1) | CO6341640A2 (fr) |
CR (1) | CR20110118A (fr) |
DO (1) | DOP2011000041A (fr) |
EA (1) | EA201100150A1 (fr) |
IL (1) | IL211034A0 (fr) |
MA (1) | MA32621B1 (fr) |
MX (1) | MX2011001477A (fr) |
NZ (1) | NZ590994A (fr) |
PE (1) | PE20110382A1 (fr) |
TW (1) | TW201018482A (fr) |
UY (1) | UY32038A (fr) |
WO (1) | WO2010017468A1 (fr) |
ZA (1) | ZA201100974B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8171134B2 (en) * | 2009-03-18 | 2012-05-01 | At&T Intellectual Property I, L.P. | Methods and apparatus to characterize and predict network health status |
KR20130028055A (ko) | 2010-01-28 | 2013-03-18 | 글락소 그룹 리미티드 | Cd 127 결합 단백질 |
US20130046015A1 (en) * | 2010-02-11 | 2013-02-21 | Robert C. Axtell | Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease |
AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
AU2014201648B2 (en) * | 2010-02-24 | 2016-05-12 | Rinat Neuroscience Corp. | Antagonist anti-il-7 receptor antibodies and methods |
CA2801509A1 (fr) | 2010-06-02 | 2011-12-08 | Dainippon Sumitomo Pharma Co., Ltd. | Medicament de traitement pour des maladies auto-immunes et des maladies allergiques |
WO2012021165A2 (fr) * | 2010-08-10 | 2012-02-16 | The Scripps Research Institute | Procédés et compositions pour traiter des désordres associés à un système immunitaire hyperactif |
EP3252076B1 (fr) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1 |
EP2583980A1 (fr) | 2011-10-19 | 2013-04-24 | Effimune | Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments |
FR2988479B1 (fr) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | Procede de determination de la susceptibilite aux infections nosocomiales |
GB2535937B (en) * | 2014-04-29 | 2017-05-31 | Bio-Cancer Treat Int Ltd | Arginase I for treating rheumatoid arthritis |
EP2955196A1 (fr) | 2014-06-10 | 2015-12-16 | Effimune | Anticorps dirigés contre CD127 |
JP2017534577A (ja) * | 2014-09-15 | 2017-11-24 | ジェネンテック, インコーポレイテッド | Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法 |
EP3207061A1 (fr) | 2014-10-18 | 2017-08-23 | Pfizer Inc | Compositions d'anticorps anti-il-7r |
WO2016142426A1 (fr) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Protéines de liaison à la tslp |
WO2017055966A1 (fr) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Compositions d'anticorps à faible viscosité |
AU2016335750B2 (en) | 2015-10-07 | 2023-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
BR112018067479A2 (pt) | 2016-02-29 | 2019-01-15 | Ose Immunotherapeutics | anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo |
RU2769352C2 (ru) | 2016-12-09 | 2022-03-30 | Осе Иммьюнотерапьютикс | Антитела и полипептиды, направленные против cd127 |
JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
BR112021014106A2 (pt) * | 2019-01-22 | 2021-10-13 | Bristol-Myers Squibb Company | Anticorpos contra subunidade alfa de il-7r e usos dos mesmos |
CN117343173A (zh) * | 2019-03-07 | 2024-01-05 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CN115279404A (zh) | 2020-02-13 | 2022-11-01 | 安进公司 | 人抗tslp抗体的配制品及治疗炎性疾病的方法 |
US20230073888A1 (en) | 2020-02-13 | 2023-03-09 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
JP2023513833A (ja) | 2020-02-18 | 2023-04-03 | アムジェン インコーポレイテッド | ヒト抗tslp抗体の製剤及びそれを使用する方法 |
MX2023006294A (es) | 2020-12-02 | 2023-06-13 | Glaxosmithkline Ip Dev Ltd | Proteinas de union a il-7 y su uso en tratamientos medicos. |
WO2023227641A1 (fr) | 2022-05-27 | 2023-11-30 | Glaxosmithkline Intellectual Property Development Limited | Utilisation de protéines de liaison au tnf-alpha et de protéines de liaison à l'il-7 dans un traitement médical |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194375A (en) * | 1989-06-15 | 1993-03-16 | Immunex Corporation | Dna encoding interleukin-7 receptors and methods of use |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994028160A1 (fr) * | 1993-06-01 | 1994-12-08 | Toray Industries, Inc. | Anticorps monoclonal, procede de production, et utilisation |
US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
WO2005123774A2 (fr) * | 2004-06-15 | 2005-12-29 | Erol Fikrig | Anticorps de polypeptides du virus du nil occidental |
WO2006052660A2 (fr) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Blocage du recepteur il-7 pour supprimer l'immunite |
PE20061391A1 (es) * | 2005-02-14 | 2007-01-09 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f |
CA2513350A1 (fr) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Traitement contre la sclerose en plaques |
GB2434578A (en) * | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
-
2009
- 2009-08-06 UY UY0001032038A patent/UY32038A/es unknown
- 2009-08-06 TW TW098126600A patent/TW201018482A/zh unknown
- 2009-08-07 NZ NZ590994A patent/NZ590994A/xx not_active IP Right Cessation
- 2009-08-07 KR KR1020117005442A patent/KR20110044777A/ko not_active Application Discontinuation
- 2009-08-07 CN CN2009801397595A patent/CN102177179A/zh not_active Withdrawn
- 2009-08-07 US US13/057,893 patent/US20110287000A1/en not_active Abandoned
- 2009-08-07 AU AU2009279471A patent/AU2009279471A1/en not_active Abandoned
- 2009-08-07 US US12/537,705 patent/US20100040616A1/en not_active Abandoned
- 2009-08-07 CA CA2733432A patent/CA2733432A1/fr not_active Abandoned
- 2009-08-07 JP JP2011522273A patent/JP2011530533A/ja not_active Withdrawn
- 2009-08-07 EP EP09791287A patent/EP2318442A1/fr not_active Withdrawn
- 2009-08-07 WO PCT/US2009/053136 patent/WO2010017468A1/fr active Application Filing
- 2009-08-07 AR ARP090103039A patent/AR072985A1/es unknown
- 2009-08-07 MX MX2011001477A patent/MX2011001477A/es unknown
- 2009-08-07 EA EA201100150A patent/EA201100150A1/ru unknown
- 2009-08-07 PE PE2011000140A patent/PE20110382A1/es not_active Application Discontinuation
- 2009-08-07 BR BRPI0916945A patent/BRPI0916945A2/pt not_active IP Right Cessation
-
2011
- 2011-02-02 DO DO2011000041A patent/DOP2011000041A/es unknown
- 2011-02-03 IL IL211034A patent/IL211034A0/en unknown
- 2011-02-07 ZA ZA2011/00974A patent/ZA201100974B/en unknown
- 2011-02-08 CL CL2011000269A patent/CL2011000269A1/es unknown
- 2011-02-11 CO CO11016609A patent/CO6341640A2/es unknown
- 2011-03-03 CR CR20110118A patent/CR20110118A/es not_active Application Discontinuation
- 2011-03-08 MA MA33682A patent/MA32621B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CO6341640A2 (es) | 2011-11-21 |
UY32038A (es) | 2010-03-26 |
CN102177179A (zh) | 2011-09-07 |
AU2009279471A1 (en) | 2010-02-11 |
TW201018482A (en) | 2010-05-16 |
EP2318442A1 (fr) | 2011-05-11 |
CR20110118A (es) | 2011-07-28 |
NZ590994A (en) | 2012-09-28 |
IL211034A0 (en) | 2011-04-28 |
CL2011000269A1 (es) | 2012-07-20 |
MX2011001477A (es) | 2011-03-25 |
US20100040616A1 (en) | 2010-02-18 |
JP2011530533A (ja) | 2011-12-22 |
AR072985A1 (es) | 2010-10-06 |
DOP2011000041A (es) | 2011-02-28 |
KR20110044777A (ko) | 2011-04-29 |
US20110287000A1 (en) | 2011-11-24 |
CA2733432A1 (fr) | 2010-02-11 |
EA201100150A1 (ru) | 2011-10-31 |
BRPI0916945A2 (pt) | 2015-11-24 |
PE20110382A1 (es) | 2011-06-27 |
WO2010017468A1 (fr) | 2010-02-11 |
ZA201100974B (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32621B1 (fr) | Traitement de maladie auto-immune et inflammatoire | |
Sarkar et al. | Molecular signatures of neuroinflammation induced by αsynuclein aggregates in microglial cells | |
Xu et al. | Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain | |
WO2012045882A3 (fr) | Composition pharmaceutique | |
MA34738B1 (fr) | Neutralisation d'anticorps anti-ccl20 | |
MA30962B1 (fr) | Anticorps antifacteurs d'humanisés et leurs utilisations. | |
MX2009003468A (es) | Anticuerpo humanizado contra beta amiloide. | |
MX2011010353A (es) | Composicion farmaceutica. | |
MA29836B1 (fr) | Proteines de fusion avec l'albumine | |
PH12011502389B1 (en) | Monoclonal antibody | |
BRPI0506890A (pt) | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo | |
IL145535A0 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
MA28969B1 (fr) | Aptameres de liaison a la famille des cytokines de l'il-12 humaine et leur utilisation comme agents therapeutiques de maladies auto-immunes | |
WO2008070666A3 (fr) | Compositions et procédés pour le traitement du cancer avec de l'adn riche en cpg et des cuprédoxines | |
RU2013137466A (ru) | Бис-met-гистоны | |
EP2438962A3 (fr) | Polynucléotides et séquences de polypeptides impliqués dans le procédé de remodelage des os | |
WO2007010080A3 (fr) | Nouveaux dendrimeres carbosilanes, leur preparation et leur utilisation | |
WO2010011283A3 (fr) | Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées | |
EP1566387A3 (fr) | Gènes impliqués dans la régulation de l'angiogenese, préparations pharmaceutiques les contenant et leurs applications | |
WO2007035722A8 (fr) | Methodes et compositions permettant de stimuler la neurogenese et d'inhiber la degenerescence neuronale | |
Teng et al. | Immunotherapies for Parkinson’s disease: progression of clinical development | |
MY149448A (en) | Interleukin-21 receptor binding proteins | |
EP2275547A3 (fr) | Polynucléotides et séquences de polypeptide impliquées dans le procédé de remodelage des os | |
WO2004050907A3 (fr) | Technique de determination de predisposition a une manifestation de maladies associees au systeme immunitaire | |
WO2008083169A3 (fr) | Compositions et procédés pour le traitement de troubles immunologiques |